Some CV drugs increase exposure, psychoactive effects of THC
A host of prescription drugs—including warfarin and other CV medications—may have potential drug interactions with the delta-9-tetrahydrocannabinol (THC) and cannabidiol in marijuana, according to an article published in the Canadian Medical Association Journal.
THC and cannabidiol are pharmacologically active cannabinoids found in cannabis, and, as more and more American states legalize recreational marijuana use, they’re fast becoming the subject of numerous research studies. Many scientists have pointed out that while the U.S. government has poured hundreds of millions of dollars into tobacco research over the past few decades, the same isn’t true for marijuana, leaving us with a rudimentary understanding of the substance at best.
Tony Antoniou, PhD, and colleagues wrote in CMAJ that one pharmacokinetic study found the CYP3A4 inhibitor ketoconazole nearly doubled concentrations of THC and cannabidiol, and similar interactions may occur with other CYP3A4 inhibitors like verapamil, a calcium channel blocker and antihypertensive agent. Antoniou and co-authors also noted that CYP2C9 inhibitors would also likely increase THC exposure and psychoactive effects of cannabis, including amiodarone, an antiarrhythmic drug, and fluoxetine, an SSRI branded most commonly as Prozac.
“Cannabidiol inhibits CYP2C19, increasing levels of the active metabolite of clobazam threefold,” the authors wrote. “Interactions with other drugs metabolized by CYP2C19 should be anticipated. Very high international normalized ratio levels and bleeding have been reported with combined use of warfarin and marijuana.”
It seems that smoking marijuana—as opposed to consuming it in food—can increase clearance of some drugs, too, Antoniou et al. said. Smoked marijuana has been shown to increase the clearance of theophylline, a bronchodilator used to treat asthma and chronic bronchitis, by as much as 40%. The authors said increased drug clearance seems to occur with regular marijuana use, defined as smoking two or more joints per week.
When cannabis is combined with sympathomimetics, a drug class of stimulants, Antoniou and colleagues said additive effects can occur, including tachycardia and hypertension. Combining marijuana with central nervous system depressants like alcohol and opioids may cause drowsiness and ataxia; a combo of cannabis and anticholinergics could result in tachycardia or confusion.
“Though further research is needed, marijuana may have serious interactions with drugs including warfarin; clobazam; central nervous system depressants and sympathomimetics; and theophylline, clozapine and olanzapine,” the authors wrote. “Patients should be advised about possible increased cannabinoid effects with concomitant CYP3A4 and 2C9 inhibitors. Alternatives that do not interact with marijuana should be selected when clinically feasible.”
After graduating from Indiana University-Bloomington with a bachelor’s in journalism, Anicka joined TriMed’s Chicago team in 2017 covering cardiology. Close to her heart is long-form journalism, Pilot G-2 pens, dark chocolate and her dog Harper Lee.